Unpacking the Astonishing Surge in Leap Therapeutics Stock (LPTX)

Written by Emily J. Thompson, Senior Investment Analyst

Source: TipRanks

Updated: Nov 13 2025

0mins

Should l Buy ?

Source: TipRanks

Stock Surge and Rebranding: Leap Therapeutics (LPTX) experienced a 368.6% stock surge after announcing a strategic shift towards digital asset investments and a rebranding to Cypherpunk Technologies, with a new ticker symbol CYPH.
Digital Asset Strategy: The company revealed a digital asset treasury strategy focused on accumulating Zcash (ZEC), using $50 million from a private placement to acquire 203,775 ZEC tokens, emphasizing its commitment to privacy-focused cryptocurrencies.
Financial Performance: For Q3 2025, Leap Therapeutics reported a net loss of $3.3 million, significantly reduced from $18.2 million in Q3 2024, attributed to lower expenses following workforce reductions and completed clinical trials.
Future Plans: The company aims to continue developing its cancer treatments while advancing its digital asset strategy, utilizing recent capital raises to support both biotech operations and digital initiatives, despite currently having no Wall Street coverage.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free